Solid Biosciences Inc., a life sciences company advancing therapies for Duchenne muscular dystrophy (including its lead gene therapy candidate SGT-001), has appointed Dr. Iman Barilero as Chief Regulatory Officer. Dr. Barilero brings with her three decades of experience as a strategic executive in the healthcare industry, working on regulatory approvals for new molecular entities in various areas of unmet medical needs across all phases of development in the US, EU, Switzerland, China, Japan and Brazil. Dr. Barilero was most recently Senior Advisor to Innouvo providing strategic regulatory guidance to scientific ventures. Prior to her most recent position, she held senior positions in Regulatory Affairs and Pharmacovigilance at Agenus and Poxel in Boston. Previously, she was Vice President, Global Head Regulatory Science & Policy at Lundbeck A/S where she played a key role in influencing the external medical and regulatory policy environment that enabled the regulatory approval of Selincro, Trintellix and contributing to approval of Rexulti and Abilify Maintena in CNS disorders.
Earlier in her career, she held various leadership roles of increasing responsibility in Pharmacology, Clinical Science, Pharmacovigilance, Regulatory Affairs & Policy engagement at Johnson & Johnson, Roche, Wyeth and Bristol Myers Squibb. She started her career as a Researcher at Gustave Roussy in France, the European Cancer Center. Dr. Barilero received her Doctorate of Pharmacy & Pharmaceutical Chemistry from the University of Damascus, Syria and her Master of Science and Doctor of Philosophy degrees in Molecular & Cellular Pharmacology, Oncology from the University of Paris VI.